Fouad Namouni, MD brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Since September 2020, he has served as President of Research & Development at Blueprint Medicines, providing key leadership as the company built a fully integrated global business and overseeing all aspects of research and development across a broad pipeline of innovative medicines in oncology/hematology and allergy/inflammation. Prior to joining Blueprint Medicines, Fouad served in leadership roles at Bristol-Myers Squibb (BMS) since 1999, including as the global development lead for the company’s practice-changing cancer immunotherapy franchise. From August 2016 to April 2020, he served as Senior Vice President and Head of Oncology Development, with responsibility for driving product development plans from early-stage clinical development through commercialization across a portfolio of nearly 30 drug candidates. Previously, he served as Head of Global Medical Affairs overseeing 1,700 employees worldwide from September 2015 to September 2017, and he served as Head of Development at BMS for Opdivo® (nivolumab) and Yervoy® (ipilimumab), immunotherapy medications used in the treatment of cancer, from January 2011 to September 2015. Prior to that, he held roles of increasing responsibility within BMS. He holds an MD from the University of Annaba Medical School in Algeria and a Pediatrics degree from Université Rene Descartes in Paris, France. In addition, he received a Pediatric Oncology and Hematology degree and an MS in clinical and experimental pharmacology from Université Paris-Sud in France.
Opdivo® and Yervoy® are registered trademarks of Bristol-Myers Squibb Company.